Taken together, the existing pool of ramatroban analogues containing fluorine groups could serve as a source of promising GPR44 18F-labeled PET tracers to investigate metabolic diseases longitudinally, monitor beta cell therapies, and evaluate pharmaceutical drug efficacy. This evidence concerns the gene PTGDR2 and metabolic disease.